Infectious Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service (Assays, Kits, & Reagents, Instruments, Services & Software), By Technology (Molecular Diagnostics, Immunoassay, Microbiology, Others), By Disease (Hepatitis, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Hospital-Acquired Infections (HAIs), Others), By End User (Hospital and Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Others), By Region and Competition, 2020-2030F

Market Overview

Global Infectious Disease Testing Market has valued at USD 34.09 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.71% through 2030F. Bacteria, parasites, viruses, and fungi are the causative agents of infectious diseases. The identification and characterization of these diseases fall under the domain of infectious disease diagnostics. Physicians and healthcare professionals primarily rely on patients' symptoms and physical examinations to detect infectious infections. A range of laboratory tests is conducted to determine the causative agents, enabling healthcare providers to administer appropriate medical treatments. Pathogens can be transmitted through direct contact, water or foodborne routes, aerosolization of infected particles in the environment, as well as via insects (such as mosquitoes) and ticks.

Individuals with compromised immune systems are particularly vulnerable to certain infections. This includes those undergoing cancer treatment or recent organ transplant recipients. The individuals who have not been vaccinated against common infectious diseases, healthcare workers, and those traveling to high-risk areas with mosquito-borne pathogens like malaria and dengue fever are at increased risk. Various laboratory tests are employed by doctors to diagnose infectious disorders. The global infectious disease testing market plays a critical role in the timely diagnosis and management of a wide array of contagious illnesses. With the growing prevalence of both viral and bacterial infections, there is a heightened need for rapid, accurate, and accessible diagnostic tools across healthcare systems. The market includes testing solutions for diseases such as HIV, hepatitis, tuberculosis, influenza, and more recently, emerging threats like COVID-19 and monkeypox. 

Technological advancements have been a key driver, particularly the adoption of molecular diagnostics, point-of-care testing, and automation in laboratories. These innovations enable quicker turnaround times, increased sensitivity and specificity, and improved disease surveillance. The expansion of decentralized healthcare settings, such as home care and remote clinics, has further spurred demand for portable and easy-to-use test kits. For instance, in December 2024, Moroccan biotech company Moldiag launched Africa’s first locally produced mpox test kits, representing a major milestone in strengthening the continent’s healthcare self-sufficiency. This development reduces dependence on imported diagnostic tools and enhances regional capacity to respond to infectious disease outbreaks. Moldiag’s initiative marks a critical advancement in building Africa’s biotechnology infrastructure and improving timely access to essential diagnostic solutions.

Key Market Drivers

Increasing Prevalence of Infectious Diseases

The global infectious disease testing market is experiencing significant growth due to the increasing prevalence of infectious diseases worldwide. The rising prevalence of infectious diseases, particularly tuberculosis (TB), is a key driver of growth in the global infectious disease testing market. According to WHO, TB caused 1.25 million deaths in 2023, making it the world’s leading infectious killer, surpassing COVID-19. With an estimated 10.8 million people falling ill globally, including many with drug-resistant TB, the demand for early, accurate, and accessible diagnostic testing continues to rise. The persistent emergence and re-emergence of infectious diseases have heightened the demand for accurate and timely diagnostic solutions. Outbreaks of diseases like COVID-19, Ebola, Zika, and antibiotic-resistant bacterial infections have underscored the need for rapid and efficient testing methods to detect, track, and manage these diseases. The globalization of travel and trade has facilitated the rapid spread of infectious agents across borders, making early detection and containment crucial to prevent outbreaks. This has driven up the demand for robust infectious disease testing infrastructure, including diagnostic assays, testing equipment, and surveillance systems.

The aging global population is more susceptible to infectious diseases, particularly due to compromised immune systems. As a result, there is a heightened focus on early detection and monitoring of infections in elderly individuals, contributing to market growth.

The rising awareness among healthcare professionals and the general public about the importance of early diagnosis and prompt treatment has also fueled demand. Timely infectious disease testing not only aids in better patient care but also helps in preventing the spread of diseases within communities. The increasing prevalence of infectious diseases, coupled with the need for rapid and accurate diagnosis, has led to substantial growth in the global infectious disease testing market. As infectious disease threats continue to evolve, the market is expected to further expand, with ongoing advancements in testing technologies and increased investment in public health infrastructure playing pivotal roles in addressing these global health challenges.

Shift in Focus from Centralized Laboratories to Decentralized Point-of-Care Testing

The global infectious disease testing market is undergoing a significant transformation due to a shift in focus from centralized laboratories to decentralized point-of-care testing (POCT). Infectious diseases can spread quickly, and timely diagnosis is crucial for effective containment and treatment. Decentralized testing allows healthcare providers to obtain results within minutes to hours, as opposed to waiting for samples to be transported to and processed in centralized laboratories, which can take days. Another significant factor is improved patient access to healthcare. POCT allows testing to be performed in various settings, including primary care clinics, emergency rooms, pharmacies, and even at home. This accessibility is particularly valuable in underserved or remote areas where centralized laboratories may be less accessible.

The adoption of POCT reduces the burden on centralized laboratories, which can become overwhelmed during outbreaks or pandemics. This decentralized approach helps distribute the testing workload, making it more manageable and efficient for healthcare systems. The global infectious disease testing market is experiencing significant growth due to the shift in focus from centralized laboratories to decentralized point-of-care testing. This transformation is driven by the need for rapid results, improved patient access to testing, pandemic response requirements, and technological advancements. As the healthcare industry continues to embrace POCT, it is likely to play an increasingly critical role in infectious disease diagnostics and management.

Research on Infectious Disease Diagnostics

Ongoing research is leading to the development of more accurate, sensitive, and rapid diagnostic technologies. According to a 2024 article, laboratory tests play a vital role in supporting clinical decisions and guiding effective treatment. Rapid and accurate diagnosis is essential for controlling the spread of infectious diseases, enabling timely intervention and improving patient outcomes. Early detection through reliable lab testing is key to effective disease management and public health response. Molecular diagnostic techniques, such as PCR and next-generation sequencing, are continuously evolving, enabling the detection of infectious agents with high precision. These advancements contribute to the expansion of the market as healthcare providers seek state-of-the-art diagnostic tools. Research into infectious disease diagnostics extends to the fields of surveillance and epidemiology. Advanced diagnostic tools are vital for tracking the prevalence, transmission, and evolution of pathogens. This research is fundamental for public health responses, including vaccination campaigns and outbreak control, thus boosting the market's growth. Research in infectious disease diagnostics often involves global collaborations among governments, healthcare organizations, academic institutions, and pharmaceutical companies. These partnerships accelerate the development and adoption of innovative diagnostic solutions, further expanding the market's reach.

Research-driven advancements in infectious disease diagnostics are pivotal in increasing the global infectious disease testing market. The pursuit of more accurate, efficient, and accessible diagnostic tools is crucial for early detection, effective treatment, and public health responses. As research continues to address the evolving landscape of infectious diseases, we can expect further growth and innovation in this critical healthcare sector.

Technological Advancement in Advanced Diagnostic Technologies

Technological advancements have led to the development of highly sensitive and specific diagnostic assays. Molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid sequencing, now offer unparalleled precision in detecting infectious agents. This increased accuracy ensures reliable and early disease detection, which is critical for effective treatment and containment. The demand for rapid infectious disease testing has grown significantly, driven by technological innovations that enable quick results. Point-of-care testing (POCT) devices and rapid antigen tests provide results within minutes, allowing for immediate decision-making in clinical settings, public health emergencies, and travel-related testing.

Automation in diagnostic laboratories has improved testing throughput and reduced the risk of errors. High-throughput automated systems can process a large volume of samples efficiently, making them essential for large-scale testing during outbreaks or pandemics. Technological advancements in advanced diagnostic technologies are revolutionizing infectious disease testing by improving accuracy, speed, and accessibility. These innovations are not only meeting the current demands of healthcare but also providing essential tools for responding to emerging infectious threats and improving patient care globally. As technology continues to evolve, the demand for advanced infectious disease testing is likely to increase further.

Download Free Sample Report

Key Market Challenges

Inadequate Reimbursements

Inadequate reimbursements within healthcare systems can indeed have a negative impact on the demand for global infectious disease testing. Reimbursements play a critical role in healthcare economics, affecting both healthcare providers and patients. When reimbursement rates for infectious disease testing are insufficient, healthcare providers, including hospitals, clinics, and laboratories, may struggle to cover the costs associated with testing. This financial strain can lead to reduced investment in testing infrastructure, limited availability of testing services, and even closures of diagnostic facilities in underserved areas.

Inadequate reimbursement rates can deter healthcare providers from offering a comprehensive range of infectious disease testing services. This may result in reduced access to critical diagnostic tests, leaving patients with limited options for early disease detection and management. Lower reimbursement rates can discourage laboratories and diagnostic companies from investing in research and development to improve testing accuracy, speed, and accessibility. This can stifle innovation and hinder the development of more advanced and cost-effective testing solutions. Reduced access to infectious disease testing due to inadequate reimbursements can exacerbate healthcare disparities, disproportionately affecting underserved populations. These disparities can result in delayed diagnoses and poorer health outcomes in vulnerable communities.

Rising Healthcare Costs Limiting the Use of Novel Diagnostic Techniques

The rising costs of healthcare present a significant challenge to the adoption and utilization of novel diagnostic techniques for infectious diseases, thereby decreasing the demand for global infectious disease testing. Healthcare systems worldwide are grappling with increasing costs, including personnel, infrastructure, and medication. The allocation of budgets for novel diagnostic technologies often competes with other essential healthcare expenditures, making it difficult to justify the investment in cutting-edge testing methods.  Many novel diagnostic techniques, such as advanced molecular testing platforms, require expensive equipment and specialized laboratory infrastructure. Acquiring, maintaining, and operating this equipment can strain healthcare budgets, particularly in resource-limited settings. Healthcare costs can exacerbate economic disparities, with individuals in lower-income brackets facing greater barriers to accessing advanced infectious disease testing. This can result in delayed diagnoses and treatment, increasing the risk of disease transmission.

Key Market Trends

Point-of-Care Testing (POCT)

POCT devices that offer rapid results and can be used outside traditional healthcare settings will continue to gain popularity. They are especially valuable in resource-limited and remote areas. POCT devices are designed to be user-friendly and portable, making them accessible even in areas with limited healthcare infrastructure. They can be used in remote clinics, field hospitals, and rural communities, bringing essential diagnostic capabilities closer to patients.

In resource-limited and remote areas, access to centralized laboratories for traditional testing can be challenging. POCT devices offer the advantage of providing immediate results, allowing healthcare providers to diagnose and initiate treatment promptly. This is crucial for managing infectious diseases effectively and preventing their spread. Rapid results from POCT devices mean that patients do not have to wait for days or weeks to receive their test results. This helps alleviate anxiety, enables timely medical decisions, and improves patient satisfaction. POCT devices often require lower initial investments compared to establishing and maintaining a fully equipped laboratory. This cost-effectiveness is particularly valuable for healthcare facilities with limited budgets.

Telemedicine

The expansion of telemedicine and remote healthcare services will increase the demand for home-based testing kits and virtual consultations with healthcare providers for infectious disease testing and monitoring. Telemedicine allows patients to access healthcare from the comfort of their homes, eliminating the need for travel and reducing wait times. Home-based testing kits align with this convenience, offering a streamlined way for patients to self-administer tests without visiting a healthcare facility. Patients with infectious diseases can benefit from continuous monitoring of their condition. Home-based testing kits enable patients to collect samples at various intervals, while virtual consultations allow healthcare providers to assess results and provide guidance on managing the disease remotely. During outbreaks or pandemics, minimizing in-person interactions can help reduce the risk of disease transmission. Telemedicine and home-based testing allow patients to receive necessary care and diagnostic services while maintaining physical distancing.Home-based testing data can be aggregated and anonymized to contribute to public health surveillance efforts. Patterns and trends in infectious disease data can help authorities monitor outbreaks and allocate resources more effectively.

Segmental Insights

Product & Service Insights

The reagents segment holds the largest market share in the infectious disease testing market due to its essential role in diagnostic procedures and recurring usage across various testing platforms. Reagents, including enzymes, antibodies, primers, and probes, are critical components used in every test to detect pathogens accurately and reliably. Unlike instruments, which are a one-time investment, reagents are consumed with each test, driving continuous demand and recurring revenue for manufacturers. The expansion of molecular diagnostics and immunoassays has significantly increased the use of specialized and high-performance reagents, particularly in real-time PCR, ELISA, and rapid antigen testing. As the number of infectious disease cases rises, especially with emerging pathogens, the need for frequent and large-scale testing boosts reagent consumption. The growing emphasis on automation and high-throughput testing in centralized laboratories further accelerates reagent usage, as these systems require consistent and precise reagent inputs. The combination of essential functionality, repeat usage, and compatibility with a wide range of platforms cements the dominant position of the reagents segment in this market.

End User Insights

The Diagnostic Reference Laboratories segment has emerged as the dominant player in the infectious disease testing market due to several key advantages. These laboratories offer high-throughput testing capabilities, enabling them to process large volumes of samples efficiently, which is particularly crucial during infectious disease outbreaks or pandemics. Their advanced infrastructure, automation, and access to skilled professionals allow for highly accurate and timely diagnostics. The reference labs often serve as central hubs for hospitals, clinics, and public health agencies that lack in-house testing capabilities. This centralized model ensures standardization, quality control, and cost-effectiveness in delivering complex diagnostic services. The growing complexity of infectious diseases and the need for specialized molecular and serological tests further drive demand for the expertise and equipment available in these laboratories. The collaborations with government bodies and global health organizations during public health emergencies have positioned diagnostic reference labs as crucial stakeholders. Their scalability, accuracy, and role in epidemiological surveillance contribute significantly to their leading position in the market.

Download Free Sample Report

Regional Insights

 The global infectious disease testing market was dominated by North America, driven by its advanced healthcare infrastructure, high disease awareness, and strong emphasis on preventive care. The region consistently invests in cutting-edge diagnostic technologies, including molecular diagnostics, next-generation sequencing, and rapid point-of-care testing, enabling quicker and more accurate detection of infectious diseases. North America also has a well-developed network of clinical laboratories, reference labs, and research institutions that support the widespread availability and adoption of diagnostic tests. The region’s dominance is further reinforced by the presence of major diagnostic companies such as Abbott, Thermo Fisher Scientific, Becton Dickinson, and bioMérieux, which continue to introduce innovative products and expand their testing portfolios. The favorable reimbursement policies, increased healthcare spending, and proactive government initiatives for managing public health threats contribute to market growth. Frequent infectious disease outbreaks, including seasonal influenza, sexually transmitted infections, and emerging pathogens, have led to increased testing volumes. These factors, combined with strong R&D activity and regulatory support, have solidified North America's leading position in the global infectious disease testing market.

Recent Developments

• In February 2025, Advanced Biological Laboratories (ABL) announced a significant milestone through a transfer and licensing agreement involving the know-how and intellectual property rights of Fastrack Diagnostics Luxembourg (FTD Ltd.). This strategic move grants Siemens Healthineers access to FTD's proprietary technologies, enhancing its capabilities in molecular diagnostics. The collaboration is expected to strengthen Siemens Healthineers’ infectious disease testing portfolio and accelerate innovation in diagnostic solutions worldwide.
• In June 2024, OLM Diagnostics, a company known for producing a range of diagnostic tests, was acquired by IMMY, a prominent distributor and manufacturer of diagnostic test kits. This acquisition aims to expand IMMY’s product portfolio and global footprint in infectious disease diagnostics, combining OLM’s innovative testing solutions with IMMY’s strong distribution and manufacturing capabilities.
• In January 2024, bioMérieux acquired LUMED, a software company specializing in clinical decision support systems. LUMED’s technology helps hospitals enhance antimicrobial stewardship and track healthcare-associated infections. This acquisition aligns with bioMérieux’s commitment to advancing data-driven solutions for infection control and improving patient outcomes through smarter, more efficient clinical decision-making tools.
• July 2022: F. Hoffmann-La Roche Ltd has unveiled a novel dual antigen and antibody diagnostic test for hepatitis C. The groundbreaking Elecsys HCV Duo is among the first immunoassay tests available commercially, enabling simultaneous and independent determination of the hepatitis C virus strain from a single human plasma or serum sample.
• February 2022: SEEGENE has been granted the CE-IVD mark by the EU regulatory authority for their Allplex SARS-CoV-2 rapid MDx Assay. This assay is suitable for deployment in airports, schools, and other large-scale institutions, delivering results in under 30 minutes.
• In June 2018, Roche Diagnostics and GE Healthcare forged a strategic agreement to co-develop and market digital clinical decision support solutions.

Key Market Players

• Biomérieux SA
• Abbott Laboratories Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Quidel Corporation
• Trinity Biotech PLC

Report Scope:

In this report, the Global Infectious Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Infectious Disease Testing Market, By Product & Service:

o   Assays

o   Kits

o   Reagents

o   Instruments

o   Services & Software

• Infectious Disease Testing Market, By Technology:

o   Molecular Diagnostics

o   Immunoassay

o   Microbiology

o   Others

• Infectious Disease Testing Market, By Disease:

o   Hepatitis

o   Human Papillomavirus (HPV)

o   Human Immunodeficiency Virus (HIV)

o   Tuberculosis (TB)

o   Hospital-Acquired Infections (HAIs)

o   Others

• Infectious Disease Testing Market, By End User:

o   Hospital and Clinical Laboratories

o   Diagnostic Reference Laboratories

o   Academic/Research Institutes

o   Others

• Infectious Disease Testing Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Infectious Disease Testing Market.

Available Customizations:

Global Infectious Disease Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Infectious Disease Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]